ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Associate Director, Clinical Data Management at Remix Therapeutics - ApplyBlast

Associate Director, Clinical Data Management

Remix Therapeutics

25 days ago

Watertown, Massachusetts, United States

Onsite

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Remix Therapeutics is seeking an Associate Director, Clinical Data Management to lead data management activities and provide vendor oversight for its lead program, REM-422. This role involves developing and executing clinical data management standards, managing CROs, and ensuring compliance with regulatory guidelines throughout the trial lifecycle. The position requires collaboration with cross-functional teams to support the development of novel therapies for oncology indications.

Responsibilities

Manage and oversee functional deliverables from data management CROs and specialized vendors
Lead data management activities from protocol review through database cleaning, lock, and archival
Establish and monitor CRO performance metrics, KPIs, and quality metrics

Skills

Qualifications

BS in a scientific, informatics, or healthcare disciplineBA in a scientific, informatics, or healthcare disciplineMaster's degreePh.D.

About Remix Therapeutics

remixtx.com

Headquarters

Watertown, Massachusetts, United States

Company Size

51-200 employees

Founded

2018

View Profile

Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies that modulate RNA processing to address disease drivers. The company's proprietary REMaster™ platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease-driving mRNAs and proteins, including historically undruggable targets. Its lead program, REM-422, is a first-in-class orally available small molecule mRNA degrader targeting MYB, with programs spanning oncology and other indications of high unmet medical need.